All‐trans retinoic acid and arsenic combination therapy benefits low‐to‐intermediate‐risk patients with newly diagnosed acute promyelocytic leukaemia: a long‐term follow‐up based on multivariate analysis. (30th March 2015) - Zhu, Hongming; Hu, Jiong; Li, Xiaoyang; Chen, Li; Zhao, Huijin; Zhou, Wei; Wang, Lining; Zhao, Xia; Zhang, Yunxiang; Chen, Yu; Sun, Huiping; Chen, Qiusheng; et al.